For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Tafamidis and Attruby represents a genuine change. These innovative therapies protect the transthyretin protein, slowing its destructive build-up and lessening the burden of the disease . Individuals are now reporting improvement… Read More